Please assess the completion status of the following clinical trial:

Trial Title: rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Apart from benign non-toxic goiter no other serious illness~* Signed proof of participation~Exclusion Criteria:~* Treatment with Levothyroxine~* Former 131I-therapy~* A thyroid volume above 100 ml or a retro-clavicular component~* Unsafe contraception~* Pregnancy or breastfeeding~* Participation in another clinical trial~* Previous allergic reaction toward rhTSH~* Suspicion of malignancy in the thyroid gland either by clinical examination, laboratory findings (a raised serum calcitonin or ionized calcium)or by fine-needle aspiration biopsy~* Physically or mental condition making it impossible to participate~* Acute ischemic heart attach within the last 3 months~* Alcohol and/or drug addicts

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rhTSH (Type: ACTIVE_COMPARATOR): proceeded by 0.1 mg rhTSH
- Placebo (Type: PLACEBO_COMPARATOR): 1 ml isotonic saline

Based on this trial design, predict the completion outcome and termination type (if applicable).